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There are many kinds of cancers of the immune system, but one, Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is particularly common and pernicious. 
Researchers at Penn Vet have shown for the first time 
that dogs that develop this disease spontaneously share the 
same aberrant activation of a critical intracellular pathway 
with humans with ABC-DLBCL.  
They also found that a drug designed to disrupt this 
pathway helps to kill tumor cells in the dogs’ cancerous 
lymph nodes.
The research was conducted by Nicola Mason, 
PhD, assistant professor of medicine at Penn Vet, 
along with Michael J. May, PhD, associate professor 
of pharmacology; postdoctoral fellow Anita Gaurnier-
Hausser, PhD; and veterinary clinical pathologist Reema 
Patel, DVM.
Their work was published 
in the May issue of the journal 
Clinical Cancer Research. 
B-cells are the part of the 
immune system that produce 
antibodies and protect 
the body against invading 
microorganisms.  In ABC-
DLBCL, the normally tightly 
regulated intracellular signaling 
pathway involved in B-cell 
activation and proliferation 
is, as the name of the disease 
suggests, constantly activated.
“This signaling pathway, 
called NF-kappaB, is critical in 
immune function; following 
an encounter with antigen, 
lymphocytes need to be 
activated and proliferate 
so that there are sufficient 
numbers to deal with the 
invading organism,” Dr. 
Mason said. “But in humans with ABC-DLBCL, and 
also in dogs with spontaneous DLBCL, this pathway is 
constitutively active and drives lymphocytes to proliferate 
continuously.“
Moreover, these malignant B-cells are resistant to 
apoptosis, or cell death. Their unchecked growth is the 
basis of the lymph node tumors that are a hallmark of the 
disease.
For many years, researchers have been investigating 
ways of interrupting the malfunctioning pathway 
that forms the tumors and provides resistance to 
chemotherapy-induced cell death. In order to test 
whether a canine model for inhibitors would have 
relevance to cancer treatment in humans, the Penn team 
first showed that the same aberrant activation of the 
NF-kappaB pathway exists in dogs.  
They then went on to demonstrate that inhibition of 
this pathway using a drug known as NEMO Binding 
Domain, or NBD, peptide led to increased cell death of 
malignant lymphocytes in a laboratory setting. The next 
step was to determine whether this peptide could similarly 
inhibit NF-kappaB activity when used in the dogs with 
the disease.
Treatment of DLBCL in dogs is similar to humans; 
in most cases, the cancer initially responds well to 
chemotherapy, but patients frequently relapse with drug-
resistant disease. The five-year survival prognosis for 
humans with ABC-DLBCL is about 50 percent, but in 
dogs the survival rate is much worse, with more than 85 
percent of dogs relapsing within the first year and the 
majority succumbing to their disease during the first or 
second round of rescue chemotherapy.
Having determined the presence of aberrant pathway 
activity in the dogs with spontaneous DLBCL and that 
inhibition of this pathway can lead to increased malignant 
cell death, the researchers performed a small pilot trial to 
determine the efficacy of the NBD peptide in dogs that 
had relapsed with drug resistant lymphoma.
The results were encouraging.
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“We injected one malignant lymph node with the 
NBD peptide and followed up with chemotherapy. One 
week after a single dose of peptide, the lymph node 
we injected was a lot smaller than the other cancerous 
lymph nodes,” Dr. Mason said. “This suggests that the 
peptide either acts alone or synergistically with rescue 
chemotherapy to kill the tumor cells.”
Testing the peptide in a live animal model, rather 
than in tumor cells taken from cell lines in a Petri dish, 
accelerates the prospects of this research leading to clinical 
treatments for both dogs and humans.  
“The identification of a comparable molecular 
pathogenesis of ABC-DLBCL between dogs and humans, 
coupled with our ability to investigate the therapeutic 
benefit of targeting this aberrant NF-kappaB pathway in 
a clinically relevant, large animal model is a great example 
of the ‘bench to bedside’ paradigm of translational 
medicine,” Dr. Mason said. “It’s been over 10 years since 
this pathway was recognized in ABC-DLBCL in humans; 
however, this is the first indication that specific inhibition 
of this pathway may have a beneficial effect in human and 
canine patients with this disease.”
Dr. Mason and her colleagues are now testing whether 
the peptide is systemically effective when administered 
intravenously.  Demonstration of safety and therapeutic 
success in this trial could not only pave the way to a 
novel approach to the treatment of this disease in pet dogs 
but also could lead to clinical trials in humans with this 
type of lymphoma.
The research was supported by the National Institutes 
of Health, American Cancer Society, Mari Lowe Center 
for Comparative Oncology and American Kennel Club’s 
Canine Health Foundation.
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Foundation Fighting Blindness has awarded Penn Vet 
Professor of Medical Genetics and Ophthalmology 
Gustavo D. Aguirre, VMD, PhD with a $230,000 
grant to continue the Penn Large Animal Model 
Translational and Research Facility. 
David Artis, PhD, associate professor, has received 
two National Institutes of Health grants (Regulation of 
protective immunity following enteric viral infection and 
Regulation and function of innate lymphoid cells).
The National Institutes of Health has granted Peter J. 
Felsburg, VMD, PhD a $626,059 grant to study gene 
therapy for canine X-lined SCID.
Dr. Ronald N. Harty, associate professor of 
microbiology, has been awarded a two-year (July 2011 
- June 2013) Developmental Research Grant from the 
NIH Middle Atlantic Regional Center of Excellence 
(MARCE) for Biodefense and Emerging Infectious 
Disease Research. His application was entitled “Novel 
FLIM-Based Optical Measurements of Filovirus Budding 
Mechanisms” and was one of four selected for funding 
out of a total of 40 applications. Dr. Bruce Freedman, 
associate professor of pathobiology is a co-primary 
investigator.
Christopher Hunter, PhD, chairman of the 
Department of Pathobiology and Tajie Harris, PhD, 
postdoctoral fellow at Penn Vet, were awarded a National 
Institutes of Health grant to study the role of chemokines 
in the T cell response to ocular toxoplasmosis.
Diane J. Gaertner, DVM, professor in the Department 
of Pathobiology, has been awarded a five-year grant 
from the National Institutes of Health/National Center 
for Research Resources for “Translational Research 
and Laboratory Animal Medicine Education for 
Veterinarians.”
The United Mitochondrial Disease Foundation (UMDF) 
has awarded Penn Vet Assistant Professor Brett A. 
Kaufman a $120,000 grant to study the role that mtDNA 
copy number control plays in the development of disease. 
Dr. Kaufman’s grant was also selected for the UMDF 
Chairman’s Award for the top grant this year.
Dr. Charles Vite, assistant professor, received $100,000 
in funding from the National Niemann-Pick Disease 
Foundation.
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